Wanbury Limited: A Resurgent Pharmaceutical Player Driving Growth in Q3 FY26

Wanbury Limited, an Indian pharmaceutical company with a significant presence in the global API market and domestic branded formulations, has reported a robust performance for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). The company's strategic turnaround initiatives are clearly yielding results, marked by substantial growth in revenue and profitability across its business segments. Revenue from operations for Q3 FY26 stood at ₹162.4 crore, reflecting a strong 21.7% year-on-year growth, while the nine-month period saw revenues increase by 13.6% to ₹485.7 crore. This growth was primarily fueled by higher API volumes, improved capacity utilization, and a steady performance in the formulations business.

The profitability metrics have shown even more impressive gains. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for Q3 FY26 surged by 91% year-on-year to ₹26.9 crore, and for 9M FY26, it increased by 65% to ₹77.6 crore. This significant improvement in margins is attributed to operating leverage, better procurement strategies, higher product yields, and enhanced solvent recovery systems. Consequently, Profit After Tax (PAT) witnessed an extraordinary growth of 1,194.3% in Q3 FY26, reaching ₹15.8 crore, and a 332.5% increase for 9M FY26, totaling ₹44.4 crore. This remarkable PAT growth underscores the company's improved operating performance, margin expansion, and reduced finance costs.

Strategic Initiatives Driving Future Growth

Wanbury's strategic focus on both its API and Formulations businesses is clearly defined. In the API segment, the company has successfully commissioned a new production block at its Tanuku facility, where manufacturing of a high-potent anaesthetic product has commenced. The first commercial shipment of this product to a European customer was dispatched in Q3 FY26. This initiative, coupled with a pipeline of four new molecules slated for commercialization each year starting FY27, positions the API business for a healthy growth phase. The company is also targeting expansion in regulated markets like the US, EU, and Brazil, focusing on high-value or large-volume molecules to optimize input costs through selective backward integration.

The Formulations business, which is in a rebuilding phase, has achieved financial break-even in 9M FY26, ahead of its envisaged FY26 target. The strategy here involves transitioning the portfolio from acute therapeutics towards specialty and chronic segments, supported by new product launches. The recent launch of the nutritional supplement C-Red and other products has shown good results. Wanbury plans geographical expansion into newer attractive markets and an increase in its field force to enhance doctor engagement and scale top brands.

Financial Discipline and Operational Excellence

Underpinning this growth is a strong emphasis on financial discipline. Wanbury has significantly de-risked its balance sheet by reducing its debt obligation by approximately 75% from a peak of ~700 Crores. This included refinancing debt, which brought down borrowing costs from 22.5% to 12.5% effective March 1, 2025, with further scope for reduction. The company's commitment to operational excellence is evident in its continuous investment in energy efficiency, zero liquid discharge (ZLD) plants, and advanced Effluent Treatment Plants (ETP). Furthermore, a 1.5 MW solar energy project at Satara is underway to meet 70% of the Patalganga site's energy requirements captively, showcasing a strong commitment to environmental stewardship.

Wanbury Limited's Q3 and 9M FY26 results reflect a successful execution of its turnaround strategy. The company is transforming into a growth-oriented entity, driven by new product launches, capacity expansions, and a relentless focus on operational efficiency and financial prudence. With a robust pipeline and strategic market expansion plans, Wanbury is well-positioned for sustained profitability and growth in the coming years, reinforcing investor confidence in its long-term vision.